Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 230 in Vertex

  1. Don't expect the V Foundation to make a billion-dollar royalty deal a la the CFFRead the original story w/Photo

    Tuesday Nov 25 | Business Journal

    Don't expect the V Foundation to make a billion-dollar royalty deal anytime in the near future; that's not a part of its playbook. Last week, the Cystic Fibrosis Foundation sold royalty rights to drugs by Vertex Pharmaceuticals for $3.3 billion , or 17 times its revenue from 2012.

    Comment?

  2. Don't expect the V Foundation to make a billion-dollar royalty deal a la the CFFRead the original story w/Photo

    Tuesday Nov 25 | Business Journal

    Don't expect the V Foundation to make a billion-dollar royalty deal anytime in the near future; that's not a part of its playbook. Last week, the Cystic Fibrosis Foundation sold royalty rights to drugs by Vertex Pharmaceuticals for $3.3 billion , or 17 times its revenue from 2012.

    Comment?

  3. Cystic Fibrosis Foundation a Gets $3.3 Billion For Royaltiesa Read the original story

    Sunday Nov 23 | Chemical & Engineering News

    The Cystic Fibrosis Foundation has sold its royalty rights for cystic fibrosis drugs developed at Vertex Pharmaceuticals for $3.3 billion. The buyer is New York City-based Royalty Pharma , which acquires drug royalty interests.

    Comment?

  4. Big Pharma - Crony Capitalism Out of ControlRead the original story

    Saturday Nov 22 | Common Dreams

    Two recent news items about the voracious drug industry should call for a supine Congress to arouse itself and initiate investigations about the pay-or-die drug prices that are far too common. The first item- a page one story in the New York Times -was about the Cystic Fibrosis Foundation, which fifteen years ago invested $150 million in the biotechnology company Vertex Pharmaceuticals to develop a drug for this serious lung disease.

    Comment?

  5. Vertex Pharmaceuticals (MA) To Present At Deutsche Bank BioFEST On December 2Read the original story

    Thursday Nov 20 | BioSpace

    Vertex Pharmaceuticals Incorporated today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET. Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the "Investors" section under the "Events and Presentations" link.

    Comment?

  6. Nasdaq 100 Movers: VRTX, ADSKRead the original story w/Photo

    Friday Nov 21 | Forbes.com

    ... Year to date, Autodesk registers a 24.0% gain. And the worst performing Nasdaq 100 component thus far on the day is Vertex Pharmaceuticals (VRTX), trading down 1.4%. Vertex Pharmaceuticals is showing a gain of 49.8% looking at the year to date ...

    Comment?

  7. Vertex to Present at Deutsche Bank BioFEST on December 2Read the original story

    Thursday Nov 20 | Customer Interaction Solutions

    Vertex Pharmaceuticals Incorporated today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET. website at www.vrtx.com in the "Investors" section under the "Events and Presentations" link.

    Comment?

  8. Prestigious Boston Companies Join Bunker Hill Community College's Learn & EarnRead the original story

    Thursday Nov 20 | Sys-Con Media

    ... Dovetail Health, EMC, Fidelity Investments, Raytheon, Staples, State Street, Suffolk Construction, UBS and Vertex Pharmaceuticals. The Learn and Earn internship program prepares BHCC students for the workplace by providing the opportunity to work in ...

    Comment?

  9. Nasdaq 100 Movers: GMCR, DLTRRead the original story w/Photo

    Thursday Nov 20 | Forbes.com

    ... ntain is showing a gain of 92.1% looking at the year to date performance. Two other components making moves today are Vertex Pharmaceuticals (VRTX), trading down 2.3%, and Activision Blizzard (ATVI), trading up 6.0% on the day.

    Comment?

  10. This Biotech Stock Is Ready To RunRead the original story w/Photo

    Wednesday Nov 19 | Benzinga

    That performance can be seen quite well with names such as Gilead Sciences , Illumina and Vertex Pharmaceuticals all having hit new highs within the last 30 days. Some have taken time getting off the ground.

    Comment?

  11. Royalty Pharma Buys Royalties On Vertex Pharmaceuticals Incorporated Drugs For $3.3 BillionRead the original story

    Tuesday Nov 18 | BioSpace

    November 19, 2014 By Krystle Vermes , BioSpace.com Breaking News Staff Royalty Pharma , a company dedicated to acquiring royalty interests in marketed and late stage biopharmaceutical products, announced today that it has acquired royalties on Vertex Pharmaceuticals ' cystic fibrosis treatments for $3.3 billion. Cystic Fibrosis Foundation Therapeutics , an affiliate of the Cystic Fibrosis foundation, owns the treatments.

    Comment?

  12. UBS hosts a conference call with Vertex PharmaceuticalsRead the original story

    Wednesday Nov 5 | Theflyonthewall.com

    Vertex submits applications for approval of Lumacaftor, Ivacaftor comibination Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for a fully co-formulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. There are approximately 22,000 people with CF ages 12 and older who have two copies of the F508del mutation in North America, Europe and Australia, including approximately 8,500 in the United States and 12,000 in Europe.

    Comment?

  13. $3.3B deal for Vertex royalities a 'Valley of Death killer' for cystic fibrosisRead the original story w/Photo

    Monday Nov 3 | Business Journal

    Patrick Marshal, father of a cystic fibrosis patient and co-founder of Portsmouth, N.H.-based biopharmaceutical recruitment and staffing firm StratAcuity Patrick Marshal calls a $3.3 billion deal involving future royalties from sales of drugs by Vertex Pharmaceuticals a "Valley of Death killer" for cystic fibrosis. The deal in question is the sale of the rights to royalties owned by the Cystic Fibrosis Foundation to Royalty Pharma, a New York firm specializing in purchasing royalty rights from large upfront cash payments.

    Comment?

  14. Payout from drug raises questions for cystic fibrosis nonprofitRead the original story w/Photo

    Wednesday Nov 19 | Worcester Telegram & Gazette

    ... Fibrosis Foundation, said the organization has expressed concern over the cost of the drug to the manufacturer, Vertex Pharmaceuticals but had no power to set the price. He said the foundation's mission has always been to get treatments to patients, ...

    Comment?

  15. Royalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatmentsRead the original story

    Wednesday Nov 5 | Theflyonthewall.com

    Vertex submits applications for approval of Lumacaftor, Ivacaftor comibination Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for a fully co-formulated combination of lumacaftor and ivacaftor for people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. There are approximately 22,000 people with CF ages 12 and older who have two copies of the F508del mutation in North America, Europe and Australia, including approximately 8,500 in the United States and 12,000 in Europe.

    Comment?

  16. With $5M In Funding, Tinder-Like Paktor Wants To Get Southeast Asia Using Dating AppsRead the original story w/Photo

    Monday Nov 17 | TechCrunch

    ... asked whether China, Japan, Korea or other countries in Asia are in the grand plans. The undisclosed round was led by Vertex Venture - a subsidiary of Singapore's Temasek Holdings, which has invested in Uber-rival Grabtaxi. Phua did not reveal ...

    Comment?

  17. Med School To Launch $750 Million CampaignRead the original story w/Photo

    Thursday Nov 13 | Harvard Crimson

    ... incorporate new learning environments and to bolster critical thinking," Joshua S. Boger, founder and former CEO of Vertex Pharmaceuticals and a member of the HMS Board of Fellows, will serve as campaign chair. The honorary co-chairs are president ...

    Comment?

  18. Are Expensive Biotech Drugs Bad For Business?Read the original story w/Photo

    Tuesday Nov 11 | Seeking Alpha

    Vertex Pharmaceuticals, with the most expensive biotech drug Kalydeco, plans trials with a combination to broaden treatment for Cystic Fibrosis. Many biologic drugs nearing FDA approval; these are "cheap" expensive drugs that are still going to provide reimbursement problems if they are widely prescribed.

    Comment?

  19. Mxa Builds a World Beating 2008 Honda CRF450Read the original story w/Photo

    Monday Nov 10 | Motocross Action

    ... a Hot Rod bottom-end kit (crankshaft, main bearings and gaskets), new Cylinder Works cylinder (with standard bore), Vertex high-compression piston and Cometic top-end gasket kit. We thought about reusing the cam, but skimping on a complete update ...

    Comment?

  20. Merck's Shortened Hep C Regimens Fall Short of Cure-Rate GoalRead the original story w/Photo

    Sunday Nov 9 | TheStreet.com

    ... cured but only after enduring debilitating side effects, including flu-like symptoms and anemia. Three years ago, Vertex Pharmaceuticals and Merck were the first companies to introduce new pills which for the first time, blocked enzymes used by the ...

    Comment?